It is reported that the PARP1 inhibitor Olaparib can promotes the binding of the transcription factor nuclear phosphoprotein (NPM1) to the PD-L1 promoter in triple-negative breast cancer cells,thereby activating PD-L1 transcription (63). Here, PARP1 is linked to triple-negative breast carcinoma.